iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm
Grant Award Details
Grant Type:
Grant Number:
DISC1-10603
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$172,621
Status:
Closed
Progress Reports
Reporting Period:
Year 1
Grant Application Details
Application Title:
iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm
Public Abstract:
Research Objective
To assess the therapeutic effect of human induced pluripotent stem cell (iPSC)-derived smooth muscle progenitors (pSMCs) for treatment of abominal aortic aneurysm (AAA).
Impact
Currently, there are no pharmacologic therapies for AAA. If successful, delivery of autologous pSMCs to the site of AAA will halt or reverse the progression towards a rupture-prone aneurysm.
Major Proposed Activities
To assess the therapeutic effect of human induced pluripotent stem cell (iPSC)-derived smooth muscle progenitors (pSMCs) for treatment of abominal aortic aneurysm (AAA).
Impact
Currently, there are no pharmacologic therapies for AAA. If successful, delivery of autologous pSMCs to the site of AAA will halt or reverse the progression towards a rupture-prone aneurysm.
Major Proposed Activities
- Derive and characterize iPSC-derived pSMCs in vitro.
- Deliver pSMCs to the abdominal aortic wall of mice with induced AAA.
- Quantitatively assess pSMC survival non-invasively by bioluminescence imaing for up to 28 days.
- Quantify the abdominal aortic diameter by ultrasound imaging for up to 28 days.
- After 28 days, euthanize animals and perform histological quantification of elastin content and pSMC cell survival.
- Perform quantitative gene expression analysis of elastin expression.
Statement of Benefit to California:
We propose to generate human induced pluripotent stem cell-derived smooth muscle progenitors for treatment of abdominal aortic aneurysm (AAA). This stem cell-based therapy will benefit California by providing a new treatment for AAA. Production of these therapeutic cells at the clinical scale will provide job opportunities to citizens of California. The benefits of this new regenerative therapy will have a tremendous impact on the state of California and to patients suffering from AAA.
Publications
- Advanced Biosystems: Endothelial Cell Mechanotransduction in the Dynamic Vascular Environment
- Front Cardiovasc Med (2018): Multicellular Interactions in 3D Engineered Myocardial Tissue. (PubMed: 30406114)
- Biomater Sci (2021): peri-Adventitial delivery of smooth muscle cells in porous collagen scaffolds for treatment of experimental abdominal aortic aneurysm. (PubMed: 34522940)